Adjuvant chemotherapy for locally advanced XXXX : updated results of the Seoul National University Hospital experience.

@entity1 @entity66 @entity900 @entity189 @entity1349
OBJECTIVES: The objective of this study was to update the long-term outcome in the treatment of locally advanced @entity189 ( @entity189 ) after radical nephroureterectomy (RNU) regarding the role of adjuvant chemotherapy. MATERIALS AND METHODS: Clinical data from 138 @entity1 who underwent RNU for locally advanced @entity189 (pT3/4 or pN+) were analyzed. RESULTS: The adjuvant chemotherapy group comprised 66 @entity1 , and other 72 @entity1 did not receive adjuvant chemotherapy. @entity900 -based chemotherapy was the most common regimen, depending on the @entity1 's eligibility and renal function. The median follow-up period was 48.7 months (interquartile range: 29.2-96.9 months). The 3-and 5-year @entity66 ( @entity66 ) rates were 76.0% and 69.9% for the non- -adjuvant chemotherapy group versus 74.6% and 54.5% for the adjuvant chemotherapy group (p=0.301, log-rank test). @entity1349 ( @entity1349 ) rates for the same time period were 70.1% and 62.9% for the non-adjuvant chemotherapy group versus 73.8% and 53.2% for the adjuvant chemotherapy group (p=0.931, log-rank test). On multivariate analysis, adjuvant chemotherapy could not predict @entity66 and @entity1349 after surgery. When @entity1 who received @entity900 -based adjuvant chemotherapy (n=59) were compared to those who did not receive adjuvant chemotherapy, similar results were found. CONCLUSIONS: There does not appear to be a significant @entity66 or @entity1349 benefit associated with adjuvant chemotherapy. Prospective randomized clinical trials are necessary to verify the effect of adjuvant chemotherapy on locally advanced @entity189 .
